Drug intelligence / Profile preview

Gripex

Development stage
Unknown
Lead developer
USP Zdrowie
Modality
Small Molecules
Administration
Oral
01

Overview

Gripex is a prominent over-the-counter (OTC) multi-symptom cold and flu medication brand owned and marketed by the Polish healthcare company USP Zdrowie. The standard formulation is a combination of three active ingredients: paracetamol, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Pseudoephedrine acts as a nasal decongestant through alpha-adrenergic receptor agonism, causing vasoconstriction in the nasal mucosa. Dextromethorphan provides antitussive effects by acting on the cough center in the medulla oblongata, primarily as a sigma-1 receptor agonist. Gripex is widely used in Poland for the symptomatic relief of fever, pain, nasal congestion, and dry cough associated with viral upper respiratory infections. The brand includes several variants with different ingredient combinations and dosages to target specific symptom profiles.

Brand names
GripexGripex MaxGripex HotGripex ControlGripex NocGripex Duo
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Gripex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gripex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call